Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term “PMF” was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
- Chronic Myeloid Leukemia
- Polycythemia Vera
- Essential Thrombocythemia
- Myeloproliferative Disorder
- Reduced Intensity Conditioning
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Tefferi, A. (2008). Primary Myelofi brosis. In: Ansell, S.M. (eds) Rare Hematological Malignancies., vol 142. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-73744-7_2
Download citation
DOI: https://doi.org/10.1007/978-0-387-73744-7_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-73743-0
Online ISBN: 978-0-387-73744-7
eBook Packages: MedicineMedicine (R0)